There was a packed house in the Mary Babb Randolph Cancer Center Atrium last Wednesday where several WVU Medicine and Cancer Institute faculty and staff and others gathered to join the Cancer Institute in honoring Dr. Richard Goldberg as the Laurence S. and Jean J. DeLynn Chair of Oncology.
WVU Cancer Institute Deputy Director and Senior Associate Vice President for Research and Graduate Education Laura Gibson called the event an opportunity to celebrate Dr. Goldberg joining WVU and his leadership for moving the Cancer Institute forward. Vice President and Executive Dean for Health Sciences Clay Marsh presented Dr. Goldberg a personalized captain’s chair in honor of his appointment as an endowed chair.
“He’s an eminent scholar, has gotten a lot of grant funding, opened two cancer centers, is an expert clinician, and has a great heart," Marsh said. “I can think of no finer leader to sit in this chair and to help build WVU’s Cancer Program for us and the state of West Virginia.”
Dr. Marsh also thanked Tea Time attendees for the work they do to help people and impact lives.
“There’s a sense of community and a sense of momentum at WVU,” Goldberg said. “We’ll accomplish great things together, and it is an honor for me to be here.”
His wife Lynda extended her appreciation. “We’ve been very welcomed and everyone has been loving and kind,” she said.
The WVU Cancer Institute is the first institution in the United States to offer intraoperative radiation therapy (IORT) to treat glioblastoma.
Several events at this year’s West Virginia Writers’ Workshop, July 20-23 at WVU, are focused on the role of writing and storytelling in health. Presenters include narrative medicine faculty from several campuses across the U.S., along with the leaders of an expressive writing program for patients at the WVU Cancer Institute. Health sciences faculty, staff and students are invited to participate in some or all of the Workshop.
WVU cancer researcher participates in study that shows promising treatments for certain patients with advanced colorectal cancer
A group of cancer researchers, including Richard Goldberg, M.D., director of the WVU Cancer Institute, released a study today in the Journal of the American Medical Association comparing the results of combinations of chemotherapy delivered with targeted therapy drugs in the treatment of people with advanced colorectal cancer who had not received prior drug treatment for their advanced disease.